Hereditary Amyloidosis Canada (HAC) is pleased to learn that Akcea Therapeutics and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully completed negotiations for Tegsedi™ (inotersen) by signing a Letter of Intent (LOI) on April 30, 2020. Tegsedi is the first of three Health Canada-approved treatments for hATTR amyloidosis to complete this important step towards public reimbursement. HAC will continue its advocacy work to ensure that those who have been diagnosed with hATTR amyloidosis have immediate, publicly funded access to all Health Canada-approved therapies, to allow for the best possible outcomes for patients living with this disease.
Now more than ever before, our community needs to work together to urge provincial and territorial governments to make treatments for hATTR amyloidosis accessible through public funding – without delay.
Join HAC’s advocacy efforts to support publicly funded access to new treatments!
Our three-part series of free advocacy webinars for patients, caregivers and family members begins on May 13. Participants will learn why advocacy is important and how you can make a difference by making your voices heard.
To register or for more information about the free advocacy webinar series, visit: https://madhattr.ca/updates-developments/
To read Akcea’s news release, visit: https://www.newswire.ca/news-releases/akcea-therapeutics-canada-confirms-letter-of-intent-with-pan-canadian-pharmaceutical-alliance-for-tegsedi-tm-inotersen-injection–855519610.html
For more information about the pCPA, visit: https://www.pcpacanada.ca/